Creo Medical Group (LON:CREO) Stock Price Down 2.2% – Should You Sell?

Shares of Creo Medical Group PLC (LON:CREO) fell 2.2% during mid-day trading on Thursday . The stock traded as low as GBX 11.75 and last traded at GBX 11.86. 143,598 shares were traded during trading, a decline of 83% from the average session volume of 858,061 shares. The stock had previously closed at GBX 12.13.

Creo Medical Group Stock Performance

The company has a debt-to-equity ratio of 6.90, a quick ratio of 2.19 and a current ratio of 5.28. The company has a market capitalization of £48.57 million, a PE ratio of -11.78 and a beta of 0.56. The company has a 50 day moving average price of GBX 14.28 and a 200 day moving average price of GBX 12.11.

Insider Activity

In other news, insider Craig Jonathan Gulliford purchased 8,036 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was acquired at an average cost of GBX 11 per share, for a total transaction of £883.96. Also, insider Richard John Rees bought 8,036 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was purchased at an average price of GBX 11 per share, with a total value of £883.96. Company insiders own 4.11% of the company’s stock.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.